PDF(Pubmed)
Abstract：
UNASSIGNED: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. It affects multiple organ systems and is associated with significant morbidity and mortality. The treatment for SLE primarily aims at controlling and remitting the disease. Baricitinib is a kinase inhibitor that selectively inhibits JAK1 and JAK2 enzymes. Recently this drug is being investigated as a potential therapeutic option for SLE.
UNASSIGNED: To analyze the efficacy of baricitinib in treating SLE.
UNASSIGNED: Search of databases identified relevant studies that reported the efficacy of baricitinib. Data of patient characteristics, intervention details, and outcomes was extracted. The data from the studies were pooled using a random-effects model. The odds ratio with their respective 95 % confidence intervals (CI) were calculated to analyze the results. A p value of <0.05 was considered statistically significant.
UNASSIGNED: 3 RCTs were included in the analysis. 1849 patients were extracted from the included studies, most of the participants were females with a mean age of 43 years. The studies showed a significant effect of Baricitinib 4 mg in achieving SRI-4 [OR = 1.42 (95 % CI: 1.01, 2.00); p = 0.04]. There was no significant association of Baricitinib 2 mg in achieving SRI-4. Both dosages of the drug did not have any significant association in achieving LLDAS as compared to placebo. Serious adverse side effects were significantly associated with Bar 4 mg as compared to Bar 2 mg.
UNASSIGNED: Our meta-analysis suggests that baricitinib might be a potential treatment option for SLE. Further large-scale clinical trials are needed to confirm our findings. Potential side effects should also be considered while the administration of this drug.
UNASSIGNED: To analyze the efficacy of baricitinib in treating SLE.
UNASSIGNED: Search of databases identified relevant studies that reported the efficacy of baricitinib. Data of patient characteristics, intervention details, and outcomes was extracted. The data from the studies were pooled using a random-effects model. The odds ratio with their respective 95 % confidence intervals (CI) were calculated to analyze the results. A p value of <0.05 was considered statistically significant.
UNASSIGNED: 3 RCTs were included in the analysis. 1849 patients were extracted from the included studies, most of the participants were females with a mean age of 43 years. The studies showed a significant effect of Baricitinib 4 mg in achieving SRI-4 [OR = 1.42 (95 % CI: 1.01, 2.00); p = 0.04]. There was no significant association of Baricitinib 2 mg in achieving SRI-4. Both dosages of the drug did not have any significant association in achieving LLDAS as compared to placebo. Serious adverse side effects were significantly associated with Bar 4 mg as compared to Bar 2 mg.
UNASSIGNED: Our meta-analysis suggests that baricitinib might be a potential treatment option for SLE. Further large-scale clinical trials are needed to confirm our findings. Potential side effects should also be considered while the administration of this drug.
摘要：
■系统性红斑狼疮（SLE）是一种慢性自身免疫性疾病。它影响多个器官系统并与显著的发病率和死亡率相关。SLE的治疗主要旨在控制和缓解疾病。Baricitinib是一种选择性抑制JAK1和JAK2酶的激酶抑制剂。最近，该药物正在作为SLE的潜在治疗选择进行研究。
■分析巴利替尼治疗SLE的疗效。
■搜索数据库确定了报告baricitinib疗效的相关研究。患者特征数据，干预细节，并提取了结果。使用随机效应模型汇总研究数据。计算其各自95%置信区间(CI)的比值比以分析结果。<0.05的p值被认为是统计学上显著的。
■3项随机对照试验包括在分析中。从纳入的研究中提取了1849名患者，大多数参与者是女性,平均年龄为43岁.研究表明，4mgBaricitinib在获得SRI-4方面具有显着效果[OR=1.42（95％CI：1.01，2.00）；p=0.04]。Baricitinib2mg与获得SRI-4没有显著关联。与安慰剂相比，两种剂量的药物在实现LLDAS方面没有任何显着关联。与Bar2mg相比，严重的不良副作用与Bar4mg显着相关。
■我们的荟萃分析表明，巴利替尼可能是SLE的潜在治疗选择。需要进一步的大规模临床试验来证实我们的发现。在服用该药物时也应考虑潜在的副作用。
■分析巴利替尼治疗SLE的疗效。
■搜索数据库确定了报告baricitinib疗效的相关研究。患者特征数据，干预细节，并提取了结果。使用随机效应模型汇总研究数据。计算其各自95%置信区间(CI)的比值比以分析结果。<0.05的p值被认为是统计学上显著的。
■3项随机对照试验包括在分析中。从纳入的研究中提取了1849名患者，大多数参与者是女性,平均年龄为43岁.研究表明，4mgBaricitinib在获得SRI-4方面具有显着效果[OR=1.42（95％CI：1.01，2.00）；p=0.04]。Baricitinib2mg与获得SRI-4没有显著关联。与安慰剂相比，两种剂量的药物在实现LLDAS方面没有任何显着关联。与Bar2mg相比，严重的不良副作用与Bar4mg显着相关。
■我们的荟萃分析表明，巴利替尼可能是SLE的潜在治疗选择。需要进一步的大规模临床试验来证实我们的发现。在服用该药物时也应考虑潜在的副作用。
